Frovatriptan
- Atc Codes:N02CC07
- CAS Codes:158930-17-7
- PHARMGKB ID:158930-17-7
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
Brand Names
Europe
Austria: Eumitan, Frovamig; Bulgaria: Relieva; Czech Republic: Fromen, Recur; Denmark: Migard, Tigreat; Estonia: Frovamig, Migard; Finland: Migard, Tigreat; France: Isimig, Tigreat; Germany: Allegro, Migard, Tigreat; Greece: Migard, Migralin, Pitunal; Hungary: Frovalon, Migard; Ireland: Frovex, Miguar; Italy: Auradol, Rilamig; Latvia: Frovamig, Migard; Lithuania: Frovamig, Migard; Netherlands: Fromirex, Frovatriptan, Migard; Poland: Migard; Portugal: Dorlise, Migard; Romania: Fromena; Slovakia: Frovamen, Migard; Slovenia: Frotan, Migard; Spain: Forvey; Sweden: Migard; UK: Migard.
North America
Canada: Frova; USA: Frova.
Drug combinations
Chemistry
Frovatriptan Succinate: C~14~H~17~N~3~O C~4~H~6~O~4~ H~2~O. Mw: 379.41. (1)(+)-(R)-2,3,4,9-Tetrahydro-3-(methylamino)-1H-carbazole-6-carboxamide butanedioate (1:1), monohydrate; (2)(+)-(R)-5,6,7,8-Tetrahydro-6-(methylamino)carbazole-3-carboxamide succinate (1:1), monohydrate. CAS-158930-17-7 (1997).
Pharmacologic Category
Antimigraine Agents; Selective Serotonin Agonists; Serotonin 5-HT~1B~, 5-HT~1D~ Receptor Agonist. (ATC-Code: N02CC07).
Mechanism of action
Selective agonist for serotonin (5-HT~1B~ and 5-HT~1D~ receptor) in cranial arteries. Precise mechanism of action not established. Causes vasoconstriction and reduces sterile inflammation associated with antidromic neuronal transmission correlating with relief of migraine.
Therapeutic use
Acute treatment of attacks of migraine with or without aura in adults.
Pregnancy and lactiation implications
There are no adequate, well-controlled studies using frovatriptan in pregnant women. Use only if potential benefit to mother outweighs potential risk to fetus.
Unlabeled use
Contraindications
Hypersensitivity to frovatriptan or any component of the formulation. Patients with ischemic heart disease or signs or symptoms of ischemic heart disease. Cerebrovascular syndromes, peripheral vascular syndromes, uncontrolled hypertension. Use within 24 hours of ergotamine derivatives, or of another 5-HT~1~ agonist. Management of hemiplegic or basilar migraine. Prophylactic treatment of migraine. Severe hepatic impairment.
Warnings and precautions
The following have been reported with 5-HT~1~ agonist administration: coronary artery vasospasm, transient ischemia, MI, ventricular tachycardia/fibrillation, cardiac arrest, death, cerebral/subarachnoid hemorrhage stroke significant elevation in blood pressure (including hypertensive crisis), peripheral vascular ischemia and colonic ischemia. Caution if administered to patients with risk factors for coronary artery disease. Use with caution in epilepsy and structural brain lesions (may lower seizure threshold). Serotonin syndrome might occur with concomitant proserotonergic drugs (e.g. SSRIs/SNRIs or triptans) or agents which reduce metabolism of frovatriptan. Concurrent use of serotonin precursors (e.g. tryptophan) not recommended.